Skip to main content
[Preprint]. 2023 Dec 13:2023.12.12.571349. [Version 1] doi: 10.1101/2023.12.12.571349

Figure 5:

Figure 5:

A) Survival outcomes in the first 1000 days (d) for 50 patients with BFB(+) but no ecDNA amplifications (n=50) in their tumors compared to outcomes for ecDNA(+) patients (n=171). P-Value = 0.02 with log rank test.

B) Maximum copy number and amplicon complexity scores for BFB amplicons sampled from Barrett’s esophagus (non-EAC) compared to esophageal adenocarcinoma (EAC) patients.